A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
NCT07082829
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Excessive Daytime Sleepiness
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Last updated on ClinicalTrials.gov
- December 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Nebraska · 1
- Site #1 · Lincoln, NE
New Jersey · 1
- Site #2 · Eatontown, NJ
New York · 1
- Site #3 · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.